Korro Bio Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Korro Bio Inc 's ROA in the second quarter of 2026?
Korro Bio Inc recorded a cumulative net loss of $-107 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -59.06%.

However, within the Healthcare sector 656 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4129, from total ROA ranking in the first quarter of 2026 at 4809.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	31.57 %	-9.19 %	-31.9 %	-26.57 %	-20.4 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-107	-113	-117	-88	-91
Return On Assets (TTM)	-59.06 %	-68.24 %	-68.58 %	-47.19 %	-45.23 %
KRRO's Total Ranking	# 4129	# 4809	# 3986	# 3992	# 3987
Total Assets (TTM) in million	237	184	140	162	180
Seq. Total Assets Change	29.28 %	31.41 %	-13.5 %	-10.46 %	-10.77 %
Seq. Net Income Change	-	-	-	-	-

KRRO's 5 Years Annual ROA >> Back to KRRO Management Effectiveness >> Compare KRRO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 299
Sector	# 657
Overall	# 4076

Return On Assets Statistics
High	Average	Low
-8.35 %	-46.09 %	-97.08 %
(Jun 30 2020)		(Sep 30 2023)

Financial Statements
Korro Bio Inc 's Assets	$ 237 million	KRRO's Balance sheet
Korro Bio Inc 's Income	$ -19 million	Quarterly KRRO's Income Statement
KRRO's Income by Division		See KRRO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-39.8 %	5.02 %	109.58 %	-39.85 %	-41.37 %
Total Assets in million	124	205	195	93	155
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-117	-84	-81	-82	-85
Annual Return On Assets	-94.92 %	-40.73 %	-41.54 %	-87.5 %	-54.64 %

KRRO's 5 Years Annual ROA >> Back to KRRO Management Effectiveness >> Compare KRRO ROA to its Competitors

More Return On Assets Ratios
KRRO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KRRO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KRRO's Competitors
Subscribers only: Roa for Korro Bio Inc 's Suppliers
Subscribers only: Return On Assets for KRRO's Customers

You may also want to know
KRRO's Roi	KRRO's Inventory Turnover Ratio	KRRO's Growth Rates	KRRO's Dividend Comparisons
	KRRO's Profitability Ratios	KRRO's Asset Turnover Ratio	KRRO's Dividend Growth
KRRO's Roe	KRRO's Valuation Ratios	KRRO's Financial Strength Ratios	KRRO's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T01:19:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.